金陵药业：福州梅峰制药厂水解蛋白注射液获再注册批准

Core Viewpoint - Jinling Pharmaceutical's subsidiary, Fuzhou Meifeng Pharmaceutical Factory, has received a re-registration approval notice for hydrolyzed protein injection from the Fujian Provincial Drug Administration, which is expected to facilitate the resumption of production and sales of the drug [1] Group 1: Company Developments - The drug approval notification number is 2025R079210, and the product specification is 500ml:25g (hydrolyzed protein), classified as a chemical drug [1] - The hydrolyzed protein injection is indicated for severe amino acid deficiency and hypoproteinemia [1] - Due to long-term suspension of production, the company must apply for an on-site inspection from the provincial drug administration before resuming production and sales [1] Group 2: Market Impact - The re-registration is beneficial for the drug's production and sales recovery, but it is noted that there will be no significant impact on the company's recent performance [1] - The production and sales of the drug are subject to uncertainties influenced by policies and market factors [1]